(4586) Stock Price

Medrex is a drug development company that creates new pharmaceuticals based on its proprietary transdermal delivery technology. The company focuses on improving drug efficacy and reducing side effects through two core platforms: "ILTS (Ionic Liquid Transdermal System)" utilizing ionic liquids, and "NCTS (Nano-sized Colloid Transdermal System)" employing drug nanoparticle technology.

Medrex operates globally with subsidiaries in the United States and Australia. Its business model involves partnering with pharmaceutical companies to develop, market, and manufacture drug candidates created using its formulation technology. Revenue is generated through upfront contract payments, milestone fees, and royalties on product sales.

The company's development pipeline includes MRX-5LBT for post-herpetic neuralgia, MRX-4TZT for spastic paralysis, and MRX-9FLT as a centrally acting analgesic. These products are undergoing clinical trials in the United States, with MRX-5LBT having received an FDA review completion notice and currently in resubmission.

Medrex is also developing "microneedle" technology, a self-administered vaccine delivery device. This technology enables painless self-injection and is expected to generate stronger immune responses compared to conventional vaccination methods. The company operates clinical trial manufacturing facilities for pharmaceutical and vaccine applications while exploring business partnerships.

Medrex's transdermal technology offers advantages including administration to patients with swallowing difficulties and avoidance of first-pass metabolism. It is particularly noted for its potential to improve quality of life in pain management and psychiatric medications.

Medrecx is advancing its drug development pipeline to maximize corporate value. In 2024, the company initiated clinical trials for "MRX-7MLL," an Alzheimer's treatment, and is progressing Phase 2 clinical trials for "Alto-101," a central nervous system disease treatment. In 2025, the company plans to advance clinical trials for multiple products, with "MRX-5LBT" particularly targeting new drug approval in the United States.

Medrecx prioritizes building partnerships with pharmaceutical companies. The company strengthens its financial foundation and pursues sustainable growth by generating revenue through licensing out its development pipeline and core technologies. Following new drug approval for "MRX-5LBT," establishing partnerships with sales partners is a critical priority.

Securing development funding is also a key strategy for Medrecx. The company raises capital through the issuance of warrants to enhance the value of its development assets. Going forward, the company will continue to secure funding through appropriate financial activities and work toward increasing corporate value.

Talent recruitment and development are integral to Medrecx's growth strategy. The company is committed to securing and developing talented personnel while fostering a corporate culture that values diversity and a spirit of challenge. This strengthens the organizational structure that supports sustainable growth.

Strengthening internal controls is a priority area for Medrecx. The company has established internal management systems appropriate to its corporate scale to ensure the appropriateness and efficiency of business operations. By implementing management systems suited to a small-scale organization, the company aims to enhance corporate credibility.